The sophorolipid class of biosurfactants are finding increasing use in personal care as well as 16 pharmaceutical products and have the potential to disrupt biofilm formation and inhibit 17 growth in a variety of clinically relevant organisms. In order to investigate potential 18 biomedical applications of sophorolipids derived from non-pathogenic organisms, we 19 fractionated and purified glycolipid biosurfactant sophorolipids produced by the yeast 20 Starmerella bombicola, which yielded both acidic C 18-1 acetylated and non-acetylated 21 congeners that were essentially free from other contaminants (>95% purity). These acidic 22 sophorolipids have antimicrobial activities against the nosocomial infective agents 23 Enterococcus faecalis and Pseudomonas aeruginosa with significant reduction in c.f.u.'s at 24 concentrations as low as 5 mgmL -1 . In addition, the sophorolipid showed similar effects 25 when combined with kanamycin or cefotaxime against the same two bacterial strains. As a 26 potential use of these sophorolipids is as a component of topically applied creams for 27 treatment of wound infections, it is clear that they must have no demonstrable adverse effect 28 on wound healing. To assess this we evaluated mammalian cell toxicity in vitro using 29 viability tests and revealed no adverse effect on either endothelial or keratinocyte derived cell 30 lines with sophorolipid concentrations <0.5 mgmL -1 . In addition, in vivo experiments using a 31 mouse skin wounding assay revealed that the time-course in healing wounds was unaffected 32 by application of sophorolipid containing creams and histological examination of regenerated 33 skin tissue confirmed that the healing process was similar to that observed in control animals, 34 with no evidence of inflammation. These results are consistent with the suggestion that acidic 35 sophorolipids can be used as a component of anti-microbial creams to reduce the risk of 36 wound infection during healing.
Introduction 39
Microbial contamination is a major obstacle to tissue healing, with cutaneous wounds in 40 particular representing one of the major routes of exposure to pathogenic bacterial strains. A 41 systematic review [1] recently identified Pseudomonas aeruginosa as the most commonly 42 reported burn wound infective pathogen. Multiple strains of multidrug resistant P. 43 aeruginosa have been isolated from burn patients in India [2] and Enterococcal in addition to 44 Pseudomonad species have been identified in cases of diabetic foot ulcer infection [3] . Many 45 medical and surgical procedures carry a significant risk of microbial infection [4, 5] , with a 46 significant proportion of these cases demonstrating bacterial drug resistance, making the 47 search for alternative approaches to treatment a clinical imperative.
49
Surfactants are a diverse group of amphiphilic compounds commonly used in detergents and 50 products for human consumption or application (such as the food industry or in cosmetic or 51 medical creams for example), although their production is heavily reliant on the 52 petrochemical industry and associated raw materials. In contrast, biosurfactants are a diverse 53 group of surfactants produced by certain species of yeast or bacteria which represent a more 54 sustainable and perceived environmentally-friendly alternative to traditional surfactants. 55 There is increasing evidence that microbial biosurfactants as well as possessing industrially 56 valuable properties of detergency, emulsification and foaming also have significant 57 bioactivities, including inhibitory or antibacterial-adjuvant activities against various 58 microorganisms [6-8; [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and specific anti-cancer activity [9] . 59 Sophorolipids (SLs) are a diverse group of glycolipid biosurfactants, characterised by a 60 sophorose molecule attached to a variable length fatty acid chain, that can be produced in 
75
The purpose of our studies was to use a highly purified preparation of acidic sophorolipid that 76 contained only the C18 congener (predominantly non-acetylated) and ascertain if it could act 77 as an antimicrobial agent or antibiotic-adjuvant against two common nosocomial infection-78 causing bacteria: Enterococcus faecalis and Pseudomonas aeruginosa. Furthermore, we also 79 explored whether these acidic sophorolipids inhibited the growth of mammalian cells 80 (endothelium, fibroblasts and keratinocytes) that are relevant to the wound healing process in 81 vitro and are compatibility with healing of uncomplicated wound in vivo .
83

Results
84
Analysis of bacterial growth with purified non-acetylated acidic sophorolipid treatment 85 Following treatment with doses of acidic sophorolipids ≥5 mg mL -1 a clear inhibitory effect 86 was observed in growth of Enterococcus faecalis: colony formation was zero with 20 mg mL -87 5 1 C18:1 NASL in two out of three experiments ( Figure 1A ). Inhibition of growth in 88 Pseudomonas aeruginosa was also evident at concentrations of ≥5 mg mL -1 acidic 89 sophorolipid; following treatment with 20 mg mL -1 C18:1 NASL colony formation was zero 90 in one out of three experiments ( Figure 1B ). Table 1 ). The highest concentration of C18:1 NASL was clearly the most effective at 100 reducing antibiotic MIC for both strains and both drugs. In fact, 4 mg mL -1 C18:1 NASL 101 alone effectively reduced growth of Pseudomonas aeruginosa. The adjuvant effect was most 102 obvious for strains treated with 4 mg mL -1 C18:1 NASL together with cefotaxime. The effect 103 of C18:1 NASL addition on kanamycin MIC was generally less marked than for cefotaxime.
104
Interestingly, the MIC of kanamycin against Pseudomonas aeruginosa was increased with 105 addition of 2 mg mL -1 C18:1 NASL.
107
In vitro cell viability assay 108 The addition of acidic C18:1 NASL to culture media in doses ranging from 0.01 -500 μg 109 mL -1 did not affect cell viability of HUVECs, HDMVECs or HaCaTs ( Figure 2 
